Cargando…

Gene Therapy Progress and Prospects: Cystic fibrosis

Since the cloning of the cystic fibrosis gene (CFTR) in 1989, 18 clinical trials have been carried out, including five in the 2 years reviewed here. Most trials demonstrated proof-of-principle for gene transfer to the airway. However, gene transfer efficiency with each of the three gene transfer age...

Descripción completa

Detalles Bibliográficos
Autores principales: Griesenbach, U, Ferrari, S, Geddes, D M, Alton, E W F W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091818/
https://www.ncbi.nlm.nih.gov/pubmed/12364999
http://dx.doi.org/10.1038/sj.gt.3301791
_version_ 1783510065919033344
author Griesenbach, U
Ferrari, S
Geddes, D M
Alton, E W F W
author_facet Griesenbach, U
Ferrari, S
Geddes, D M
Alton, E W F W
author_sort Griesenbach, U
collection PubMed
description Since the cloning of the cystic fibrosis gene (CFTR) in 1989, 18 clinical trials have been carried out, including five in the 2 years reviewed here. Most trials demonstrated proof-of-principle for gene transfer to the airway. However, gene transfer efficiency with each of the three gene transfer agents (adenovirus (Ad), adeno-associated virus 2 (AAV2) and cationic liposomes) was low, and most likely insufficient to achieve clinical benefit. Here, we will review the clinical and pre-clinical progress for the last 2 years (2000–2001) and briefly speculate on future prospects for the next 2 in CF gene therapy.
format Online
Article
Text
id pubmed-7091818
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70918182020-03-24 Gene Therapy Progress and Prospects: Cystic fibrosis Griesenbach, U Ferrari, S Geddes, D M Alton, E W F W Gene Ther Article Since the cloning of the cystic fibrosis gene (CFTR) in 1989, 18 clinical trials have been carried out, including five in the 2 years reviewed here. Most trials demonstrated proof-of-principle for gene transfer to the airway. However, gene transfer efficiency with each of the three gene transfer agents (adenovirus (Ad), adeno-associated virus 2 (AAV2) and cationic liposomes) was low, and most likely insufficient to achieve clinical benefit. Here, we will review the clinical and pre-clinical progress for the last 2 years (2000–2001) and briefly speculate on future prospects for the next 2 in CF gene therapy. Nature Publishing Group UK 2002-10-03 2002 /pmc/articles/PMC7091818/ /pubmed/12364999 http://dx.doi.org/10.1038/sj.gt.3301791 Text en © Macmillan Publishers Limited 2002 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Griesenbach, U
Ferrari, S
Geddes, D M
Alton, E W F W
Gene Therapy Progress and Prospects: Cystic fibrosis
title Gene Therapy Progress and Prospects: Cystic fibrosis
title_full Gene Therapy Progress and Prospects: Cystic fibrosis
title_fullStr Gene Therapy Progress and Prospects: Cystic fibrosis
title_full_unstemmed Gene Therapy Progress and Prospects: Cystic fibrosis
title_short Gene Therapy Progress and Prospects: Cystic fibrosis
title_sort gene therapy progress and prospects: cystic fibrosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091818/
https://www.ncbi.nlm.nih.gov/pubmed/12364999
http://dx.doi.org/10.1038/sj.gt.3301791
work_keys_str_mv AT griesenbachu genetherapyprogressandprospectscysticfibrosis
AT ferraris genetherapyprogressandprospectscysticfibrosis
AT geddesdm genetherapyprogressandprospectscysticfibrosis
AT altonewfw genetherapyprogressandprospectscysticfibrosis